Journal

Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019?

Read time: 1 mins

Published:24th Jun 2019

Author: Ramacciotti E, Agati LB, Caffaro RA, Volpiani GG, Lopes RD, Comerota AJ et al.

Source: Clinical and Applied Thrombosis/Hemostasis

Availability: Free full text

Ref.:Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619856433.

DOI:10.1177/1076029619856433.

Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019?

Direct oral anticoagulants (DOACs) are now widely used for the management of venous thromboembolism (VTE) that now includes cancer-associated thrombosis. This review summarizes recent data on VTE prophylaxis and treatment, new challenges, guidelines, and updates as well as the current place for DOACs on the emerging cancer-associated VTE management landscape.

Read abstract on library site Access full article